Display options
Cite
Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061302.
Djureinovic, D., Wang, M., & Kluger, H. M. (2021). Agonistic CD40 Antibodies in Cancer Treatment. Cancers, 13(6), . https://doi.org/10.3390/cancers13061302
Djureinovic, Dijana, et al. "Agonistic CD40 Antibodies in Cancer Treatment." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061302
Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061302. PMID: 33804039; PMCID: PMC8000216.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Mar 15;13(6). doi: 10.3390/cancers13061302.

Agonistic CD40 Antibodies in Cancer Treatment.

Cancers

Dijana Djureinovic, Meina Wang, Harriet M Kluger

Affiliations

  1. Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.

PMID: 33804039 PMCID: PMC8000216 DOI: 10.3390/cancers13061302

Abstract

CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presentation, maturation (licensing) of dendritic cells, and activation of CD8+ T cells. Here we analyzed gene expression data from The Cancer Genome Atlas in melanoma, renal cell carcinoma, and pancreatic adenocarcinoma and found correlations between CD40 and several genes involved in antigen presentation and T cell function, supporting further exploration of CD40 agonists to treat cancer. Agonist CD40 antibodies have induced anti-tumor effects in several tumor models and the effect has been more pronounced when used in combination with other treatments (immune checkpoint inhibition, chemotherapy, and colony-stimulating factor 1 receptor inhibition). The reduction in tumor growth and ability to reprogram the tumor microenvironment in preclinical models lays the foundation for clinical development of agonistic CD40 antibodies (APX005M, ChiLob7/4, ADC-1013, SEA-CD40, selicrelumab, and CDX-1140) that are currently being evaluated in early phase clinical trials. In this article, we focus on CD40 expression and immunity in cancer, agonistic human CD40 antibodies, and their pre-clinical and clinical development. With the broad pro-inflammatory effects of CD40 and its ligand on dendritic cells and macrophages, and downstream B and T cell activation, agonists of this pathway may enhance the anti-tumor activity of other systemic therapies.

Keywords: CD40; agonistic antibodies; cancer; innate immunity

References

  1. Cell. 2017 Feb 9;168(4):707-723 - PubMed
  2. Oncoimmunology. 2018 Aug 20;7(10):e1468956 - PubMed
  3. Am J Transplant. 2003 Nov;3(11):1341-9 - PubMed
  4. Blood. 2009 Sep 24;114(13):2649-56 - PubMed
  5. Cancer Immunol Res. 2015 Apr;3(4):399-411 - PubMed
  6. Lancet Oncol. 2021 Jan;22(1):118-131 - PubMed
  7. Lancet Oncol. 2017 Jan;18(1):31-41 - PubMed
  8. Science. 2011 Mar 25;331(6024):1612-6 - PubMed
  9. Clin Cancer Res. 2017 Aug 1;23(15):4270-4279 - PubMed
  10. Immunol Cell Biol. 2011 Feb;89(2):255-67 - PubMed
  11. Cancer Res. 2016 Nov 1;76(21):6266-6277 - PubMed
  12. Int J Cancer. 2019 Sep 1;145(5):1189-1199 - PubMed
  13. Nat Med. 2002 Mar;8(3):247-52 - PubMed
  14. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):180-185 - PubMed
  15. Int J Biol Macromol. 2019 Mar 1;124:846-853 - PubMed
  16. Cancer Res. 2006 Jun 15;66(12):6395-404 - PubMed
  17. Oncoimmunology. 2013 Jan 1;2(1):e23033 - PubMed
  18. Clin Cancer Res. 2011 Apr 15;17(8):2270-80 - PubMed
  19. Haematologica. 2010 May;95(5):845-8 - PubMed
  20. Cancer Biol Ther. 2010 Nov 15;10(10):983-93 - PubMed
  21. Cytokine. 2001 Nov 21;16(4):131-42 - PubMed
  22. Hum Immunol. 1993 Jan;36(1):34-40 - PubMed
  23. Cell Rep. 2016 Jun 21;15(12):2719-32 - PubMed
  24. J Hepatol. 2020 Dec 1;: - PubMed
  25. Eur J Immunol. 2005 Nov;35(11):3307-19 - PubMed
  26. Sci Transl Med. 2012 Mar 28;4(127):127ra37 - PubMed
  27. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551 - PubMed
  28. Cancer Res. 2018 Oct 15;78(20):5891-5900 - PubMed
  29. Int Rev Immunol. 2012 Aug;31(4):267-78 - PubMed
  30. Science. 2002 Sep 20;297(5589):2060-3 - PubMed
  31. Cancer Res. 2003 Aug 1;63(15):4490-6 - PubMed
  32. Lancet Oncol. 2019 Feb;20(2):297-310 - PubMed
  33. Clin Cancer Res. 2015 Mar 15;21(6):1321-8 - PubMed
  34. J Immunol. 2001 Jan 1;166(1):89-94 - PubMed
  35. J Exp Med. 2018 Mar 5;215(3):877-893 - PubMed
  36. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167 - PubMed
  37. J Exp Med. 1998 Dec 7;188(11):2175-80 - PubMed
  38. Annu Rev Immunol. 1994;12:881-922 - PubMed
  39. Cancer Immunol Res. 2014 Jan;2(1):19-26 - PubMed
  40. Int J Cancer. 2014 Oct 15;135(8):1983-8 - PubMed
  41. Nat Rev Immunol. 2017 Feb;17(2):97-111 - PubMed
  42. Nat Med. 2004 May;10(5):540-4 - PubMed
  43. Clin Cancer Res. 2015 Mar 1;21(5):1115-26 - PubMed
  44. Cancer Cell. 2015 Jan 12;27(1):138-48 - PubMed
  45. Clin Cancer Res. 2013 Nov 15;19(22):6286-95 - PubMed
  46. J Immunol. 2016 Jul 1;197(1):179-87 - PubMed
  47. Lancet Oncol. 2016 Nov;17(11):1558-1568 - PubMed
  48. J Immunol. 2008 May 15;180(10):6527-35 - PubMed
  49. Nat Immunol. 2011 Jul 19;12(8):695-708 - PubMed
  50. J Immunol. 1999 Jul 15;163(2):787-93 - PubMed
  51. J Immunol. 2011 Aug 15;187(4):1754-63 - PubMed
  52. N Engl J Med. 2018 Apr 05;378(14):1277-1290 - PubMed
  53. Cancer Immunol Immunother. 2019 Feb;68(2):233-245 - PubMed
  54. J Immunother Cancer. 2020 Oct;8(2): - PubMed
  55. Int J Cancer. 2003 Feb 10;103(4):466-74 - PubMed
  56. Immunobiology. 2020 Mar;225(2):151899 - PubMed
  57. Cancer Cell. 2018 Apr 9;33(4):664-675.e4 - PubMed
  58. J Clin Oncol. 2007 Mar 1;25(7):876-83 - PubMed
  59. J Exp Med. 1996 Jan 1;183(1):159-67 - PubMed
  60. Cancer Cell. 2016 Jun 13;29(6):820-831 - PubMed
  61. J Mol Biol. 2016 Jul 17;428(14):2860-79 - PubMed
  62. Immunol Rev. 1996 Oct;153:85-106 - PubMed
  63. Mol Cell Biol. 2000 Aug;20(15):5503-15 - PubMed
  64. Cancer Cell. 2018 Apr 9;33(4):563-569 - PubMed
  65. Circ Res. 2011 Nov 11;109(11):1269-79 - PubMed
  66. J Exp Med. 1987 Oct 1;166(4):1084-97 - PubMed
  67. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691-6 - PubMed
  68. Science. 2011 Aug 19;333(6045):1030-4 - PubMed
  69. Blood. 1998 Dec 1;92(11):4150-66 - PubMed
  70. Cancer Cell. 2016 Sep 12;30(3):500 - PubMed
  71. Cancer Immunol Res. 2015 Mar;3(3):236-44 - PubMed
  72. Immunology. 1994 Nov;83(3):430-7 - PubMed
  73. N Engl J Med. 2017 Oct 5;377(14):1345-1356 - PubMed
  74. Nat Med. 1999 Jul;5(7):780-7 - PubMed
  75. N Engl J Med. 2015 Jul 2;373(1):23-34 - PubMed
  76. J Exp Med. 2018 Mar 5;215(3):859-876 - PubMed
  77. EBioMedicine. 2021 Feb;64:103160 - PubMed
  78. N Engl J Med. 2019 Nov 21;381(21):2020-2031 - PubMed
  79. Cancer Immunol Res. 2014 Nov;2(11):1051-8 - PubMed
  80. Clin Cancer Res. 2011 Jul 15;17(14):4672-81 - PubMed
  81. Immunol Rev. 2009 May;229(1):152-72 - PubMed
  82. Oncotarget. 2016 Apr 5;7(14):18508-20 - PubMed
  83. Cancer Res. 2018 Aug 1;78(15):4282-4291 - PubMed
  84. Annu Rev Immunol. 1998;16:111-35 - PubMed
  85. Front Immunol. 2013 Nov 15;4:376 - PubMed
  86. J Immunol. 1998 Feb 1;160(3):1224-32 - PubMed
  87. Oncol Lett. 2011 Jul;2(4):583-589 - PubMed
  88. Nat Commun. 2017 Nov 10;8(1):1404 - PubMed
  89. J Immunol. 2008 Sep 1;181(5):3422-31 - PubMed
  90. J Exp Med. 2004 Mar 15;199(6):775-84 - PubMed
  91. J Clin Oncol. 2017 Dec 1;35(34):3851-3858 - PubMed
  92. Annu Rev Immunol. 2002;20:55-72 - PubMed
  93. J Allergy Clin Immunol. 2002 Sep;110(3):421-8 - PubMed
  94. Nat Med. 1996 Oct;2(10):1096-103 - PubMed
  95. Front Cardiovasc Med. 2017 Jun 20;4:40 - PubMed
  96. Immunology. 2001 Jan;102(1):39-43 - PubMed
  97. Immunology. 2002 Aug;106(4):456-63 - PubMed
  98. Oral Oncol. 2014 May;50(5):457-67 - PubMed
  99. J Exp Med. 2001 Sep 17;194(6):769-79 - PubMed
  100. Curr Opin Hematol. 2003 Jul;10(4):272-8 - PubMed
  101. J Exp Med. 2002 Dec 16;196(12):1627-38 - PubMed
  102. Nat Immunol. 2013 Oct;14(10):1014-22 - PubMed
  103. Eur J Immunol. 2013 Oct;43(10):2718-29 - PubMed
  104. Cancer Immunol Res. 2017 Mar;5(3):182-190 - PubMed
  105. Trends Genet. 1995 Feb;11(2):69-74 - PubMed
  106. Nature. 1998 Jun 4;393(6684):480-3 - PubMed
  107. J Immunol. 2004 May 15;172(10):6047-56 - PubMed
  108. J Immunol. 2011 Apr 1;186(7):4183-90 - PubMed
  109. Nat Med. 2020 Feb;26(2):193-199 - PubMed
  110. Oncology (Williston Park). 2010 Dec;24(14):1280-8 - PubMed
  111. Cancer Immunol Res. 2014 Jan;2(1):80-90 - PubMed
  112. Ann Oncol. 2015 Dec;26(12):2483-90 - PubMed

Publication Types

Grant support